MX2023007192A - Inhibidores de prmt5. - Google Patents
Inhibidores de prmt5.Info
- Publication number
- MX2023007192A MX2023007192A MX2023007192A MX2023007192A MX2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- prmts
- compounds
- formula
- prmt5
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 abstract 2
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen en el presente documento inhibidores novedosos de PRMT5 de Fórmula I y sales farmacéuticamente aceptables de los mismos, así como composiciones farmacéuticas de los mismos. Los compuestos de la presente invención son útiles para inhibir la actividad de PRMT5 y pueden tener uso en el tratamiento de trastornos proliferativos, metabólicos y sanguíneos. Los compuestos de Fórmula I tienen la siguiente estructura: (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063126416P | 2020-12-16 | 2020-12-16 | |
PCT/US2021/063540 WO2022132914A1 (en) | 2020-12-16 | 2021-12-15 | Prmts inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007192A true MX2023007192A (es) | 2023-07-03 |
Family
ID=79927288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007192A MX2023007192A (es) | 2020-12-16 | 2021-12-15 | Inhibidores de prmt5. |
Country Status (17)
Country | Link |
---|---|
US (2) | US11845760B2 (es) |
EP (1) | EP4263545A1 (es) |
JP (2) | JP7487421B2 (es) |
KR (1) | KR20230121820A (es) |
CN (1) | CN116888120A (es) |
AR (1) | AR124369A1 (es) |
AU (1) | AU2021400942A1 (es) |
CA (1) | CA3204823A1 (es) |
CL (1) | CL2023001738A1 (es) |
CO (1) | CO2023008167A2 (es) |
CR (1) | CR20230310A (es) |
IL (1) | IL303451A (es) |
MX (1) | MX2023007192A (es) |
PE (1) | PE20231295A1 (es) |
TW (1) | TW202233183A (es) |
UY (1) | UY39565A (es) |
WO (1) | WO2022132914A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
EP4188920A1 (en) | 2020-07-31 | 2023-06-07 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
MX2024002589A (es) * | 2021-08-30 | 2024-04-30 | Amgen Inc | Proceso para sintetizar derivados de naftiridina y compuestos intermedios de los mismos. |
WO2023196545A1 (en) * | 2022-04-08 | 2023-10-12 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
WO2024002263A1 (zh) * | 2022-06-30 | 2024-01-04 | 南京明德新药研发有限公司 | 氨基取代的杂芳基衍生物及其应用 |
WO2024002377A1 (zh) * | 2022-07-01 | 2024-01-04 | 上海赛岚生物科技有限公司 | 一类prmt5抑制剂及其用途 |
WO2024021957A1 (zh) * | 2022-07-26 | 2024-02-01 | 上海和誉生物医药科技有限公司 | 一种prmt5抑制剂及其制备方法和药学上的应用 |
WO2024027370A1 (zh) * | 2022-08-03 | 2024-02-08 | 上海和誉生物医药科技有限公司 | 一种含氮三稠环prmt5抑制剂,其制备方法和药学上的用途 |
WO2024038004A1 (en) | 2022-08-15 | 2024-02-22 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
WO2024037459A1 (zh) * | 2022-08-18 | 2024-02-22 | 南京明德新药研发有限公司 | 含酰胺的杂环衍生物及其应用 |
CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
WO2024067445A1 (zh) * | 2022-09-26 | 2024-04-04 | 上海湃隆生物科技有限公司 | 新型prmt5抑制剂及其应用 |
CN115677708A (zh) * | 2022-10-19 | 2023-02-03 | 五邑大学 | 一种吡咯并喹喔啉的制备方法 |
WO2024118897A1 (en) * | 2022-11-30 | 2024-06-06 | Amgen Inc. | Cancer treatments using a prmt5 inhibitor and a mat2a inhibitor |
WO2024123740A1 (en) * | 2022-12-05 | 2024-06-13 | Amgen Inc. | Solid forms of naphthyridine compounds |
WO2024131901A1 (zh) * | 2022-12-23 | 2024-06-27 | 深圳微芯生物科技股份有限公司 | 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用 |
WO2024153128A1 (en) * | 2023-01-18 | 2024-07-25 | Shanghai Antengene Corporation Limited | Prmt5 inhibiting compounds and uses thereof |
WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
WO2024182466A1 (en) * | 2023-02-28 | 2024-09-06 | Amgen Inc. | Process for synthesizing naphthyridine derivatives and intermediates thereof |
CN118221682A (zh) * | 2023-05-17 | 2024-06-21 | 四川科伦博泰生物医药股份有限公司 | 酰胺化合物、包含其的药物组合物及其制备方法和用途 |
US11845749B1 (en) | 2023-07-13 | 2023-12-19 | King Faisal University | Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106573932B (zh) | 2014-08-22 | 2019-07-30 | 默克专利股份公司 | 吲唑类 |
UA126481C2 (uk) | 2017-08-09 | 2022-10-12 | Прел'Юд Терап'Ютікс, Інкорпорейтід | Селективний інгібітор протеїнової аргінінметилтрансферази 5 (prmt5) |
WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
JP2023513580A (ja) * | 2020-02-12 | 2023-03-31 | アムジェン インコーポレイテッド | 新規prmt5阻害剤 |
-
2021
- 2021-12-15 AU AU2021400942A patent/AU2021400942A1/en active Pending
- 2021-12-15 KR KR1020237023776A patent/KR20230121820A/ko unknown
- 2021-12-15 TW TW110146964A patent/TW202233183A/zh unknown
- 2021-12-15 EP EP21847813.9A patent/EP4263545A1/en active Pending
- 2021-12-15 MX MX2023007192A patent/MX2023007192A/es unknown
- 2021-12-15 CN CN202180093453.1A patent/CN116888120A/zh active Pending
- 2021-12-15 PE PE2023001893A patent/PE20231295A1/es unknown
- 2021-12-15 US US17/552,016 patent/US11845760B2/en active Active
- 2021-12-15 AR ARP210103508A patent/AR124369A1/es unknown
- 2021-12-15 UY UY0001039565A patent/UY39565A/es unknown
- 2021-12-15 JP JP2023535834A patent/JP7487421B2/ja active Active
- 2021-12-15 IL IL303451A patent/IL303451A/en unknown
- 2021-12-15 CA CA3204823A patent/CA3204823A1/en active Pending
- 2021-12-15 WO PCT/US2021/063540 patent/WO2022132914A1/en active Application Filing
- 2021-12-15 CR CR20230310A patent/CR20230310A/es unknown
-
2023
- 2023-06-14 CL CL2023001738A patent/CL2023001738A1/es unknown
- 2023-06-22 CO CONC2023/0008167A patent/CO2023008167A2/es unknown
- 2023-11-06 US US18/502,780 patent/US20240092794A1/en active Pending
-
2024
- 2024-05-07 JP JP2024075101A patent/JP2024102236A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024102236A (ja) | 2024-07-30 |
US20240092794A1 (en) | 2024-03-21 |
US11845760B2 (en) | 2023-12-19 |
AR124369A1 (es) | 2023-03-22 |
WO2022132914A1 (en) | 2022-06-23 |
JP2023550530A (ja) | 2023-12-01 |
JP7487421B2 (ja) | 2024-05-20 |
IL303451A (en) | 2023-08-01 |
TW202233183A (zh) | 2022-09-01 |
CO2023008167A2 (es) | 2023-07-21 |
CL2023001738A1 (es) | 2023-11-17 |
UY39565A (es) | 2022-06-30 |
CR20230310A (es) | 2023-09-01 |
KR20230121820A (ko) | 2023-08-21 |
PE20231295A1 (es) | 2023-08-22 |
AU2021400942A1 (en) | 2023-07-06 |
US20220194955A1 (en) | 2022-06-23 |
CN116888120A (zh) | 2023-10-13 |
CA3204823A1 (en) | 2022-06-23 |
EP4263545A1 (en) | 2023-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023007192A (es) | Inhibidores de prmt5. | |
MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
CR20230286A (es) | Inhibidores de prmt5 novedosos | |
MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
CR20220230A (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
AU2011297889A8 (en) | Pharmaceutically active compounds as Axl inhibitors | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
EA201991916A1 (ru) | 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ | |
MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
MX2021014372A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
JOP20220227A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
MX2024004444A (es) | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). | |
MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
MX2022013482A (es) | Compuestos utiles para inhibir la quinasa ret. | |
MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
NZ777925A (en) | Deoxy- cytidine or uridine derivatives for use in cancer therapies |